Chronic kidney disease (CKD) and dialysis patients often have to manage a complex regimen of prescription drugs to maintain their health, but the cost of these drugs can be a significant burden. A new law passed in 2021 could change that and potentially save thousands on prescription drug costs for CKD and dialysis patients.
The new law expands the income limits for those who can receive extra help with their Part D costs, also known as the Medicare Prescription Drug Benefit. This means that more CKD and dialysis patients will now qualify for assistance, making it easier for them to afford the drugs they need.
To be eligible for the expanded assistance, CKD and dialysis patients must have a household income of less than or equal to 150% of the federal poverty level. They must also be enrolled in a Part D plan and have limited savings and resources.
The potential savings for those who qualify for the expanded assistance are significant, with an average of thousands of dollars per year on prescription drug costs. This is a huge relief, particularly for CKD and dialysis patients who already have to deal with high medical costs.
CKD and dialysis patients often have to manage multiple prescriptions and the cost of these drugs can be a significant burden, but now, with this new law, they can get the extra help they need to cover the costs. Don't miss out on this opportunity to save thousands on your prescription drugs costs, check your eligibility and apply for the expanded assistance today.
Subscribe
Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.
Did this answer your question?
More News
A study supported by the National Institutes of Health found that people who experienced acute kidney injury (AKI) during a hospitalization, including those admitted with AKI or who developed AKI in the hospital, were more likely to revisit the hospital or die shortly after discharge, compared to people hospitalized without AKI. AKI is a sudden loss of kidney function that usually lasts for a short time. The research, funded by NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), was published in the American Journal of Kidney Diseases(link is external)